Combining 2 Assessments of Breast Cancer Recurrence Risk May Help Guide Use of Adjuvant Chemotherapy

Combining 2 Assessments of Breast Cancer Recurrence Risk May Help Guide Use of Adjuvant Chemotherapy
Adding an assessment of a woman's clinical risk to Genomic Health's genomic test Oncotype DX to estimate the likelihood of breast cancer recurrence may spare more young women from having to undergo chemotherapy after surgery than originally thought. These findings come from a secondary analysis of the landmark study TAILORx, which also revealed that combining the two assessments can help identify young women who are likely to benefit from more effective anti-estrogen hormonal therapy. Based on TRIALx results, the American Society of Clinical Oncology (ASCO) updated its recommendations to highlight the advantages of using Oncotype DX to help physicians determine which women should or should not undergo adjuvant chemotherapy for early-stage, hormone receptor (HR)-positive, node-negative breast cancer. The new analysis, titled "Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx,"was recently presented by
Subscribe or to access all post and page content.